Studying an antibiotic for infections in blood cancer patients
Treatments studied
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years old or older.
- You have a blood cancer (like leukemia, lymphoma, myeloma, or MDS) or have had a stem cell transplant.
- Your doctor has prescribed a specific antibiotic called ceftazidime-avibactam to treat a bacterial infection.
- The antibiotic treatment is planned for at least 3 days.
- You agree to have extra blood draws and other samples taken to monitor the drug levels and infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two IV antibiotics (aztreonam and avibactam) against the best available treatment for serious gram-negative infections. It may help people who are hospitalized and need IV antibiotics, especially when the infection is caused by certain gram-negative bacteria.
This trial tests a specific antibiotic combination (ceftazidime-avibactam) in patients with serious infections that are resistant to other antibiotics, while they are in intensive care. The goal is to see how well this treatment works for critically ill patients.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
Hear when a new Gram-Negative Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.